tetano
Editor, Senior Moderator
PLoS One
. 2021 Nov 15;16(11):e0258645.
doi: 10.1371/journal.pone.0258645. eCollection 2021.
Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins
Yengkhom Damayanti Devi[SUP] 1 [/SUP], Himanshu Ballav Goswami[SUP] 1 [/SUP], Sushmita Konwar[SUP] 1 [/SUP], Chandrima Doley[SUP] 1 [/SUP], Anutee Dolley[SUP] 1 [/SUP], Arpita Devi[SUP] 1 [/SUP], Chen Chongtham[SUP] 1 2 [/SUP], Dikshita Dowerah[SUP] 3 [/SUP], Vashkar Biswa[SUP] 4 [/SUP], Latonglila Jamir[SUP] 5 [/SUP], Aditya Kumar[SUP] 1 [/SUP], Siddhartha Shankar Satapathy[SUP] 6 7 [/SUP], Suvendra Kumar Ray[SUP] 1 7 [/SUP], Ramesh Chandra Deka[SUP] 3 7 [/SUP], Robin Doley[SUP] 1 [/SUP], Manabendra Mandal[SUP] 1 7 [/SUP], Sandeep Das[SUP] 4 [/SUP], Chongtham Shyamsunder Singh[SUP] 8 [/SUP], Partha Pratim Borah[SUP] 9 [/SUP], Pabitra Nath[SUP] 10 [/SUP], Nima D Namsa[SUP] 1 7 [/SUP]
Affiliations
Abstract
All approved coronavirus disease 2019 (COVID-19) vaccines in current use are safe, effective, and reduce the risk of severe illness. Although data on the immunological presentation of patients with COVID-19 is limited, increasing experimental evidence supports the significant contribution of B and T cells towards the resolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the availability of several COVID-19 vaccines with high efficacy, more effective vaccines are still needed to protect against the new variants of SARS-CoV-2. Employing a comprehensive immunoinformatic prediction algorithm and leveraging the genetic closeness with SARS-CoV, we have predicted potential immune epitopes in the structural proteins of SARS-CoV-2. The S and N proteins of SARS-CoV-2 and SARS-CoVs are main targets of antibody detection and have motivated us to design four multi-epitope vaccines which were based on our predicted B- and T-cell epitopes of SARS-CoV-2 structural proteins. The cardinal epitopes selected for the vaccine constructs are predicted to possess antigenic, non-allergenic, and cytokine-inducing properties. Additionally, some of the predicted epitopes have been experimentally validated in published papers. Furthermore, we used the C-ImmSim server to predict effective immune responses induced by the epitope-based vaccines. Taken together, the immune epitopes predicted in this study provide a platform for future experimental validations which may facilitate the development of effective vaccine candidates and epitope-based serological diagnostic assays.
. 2021 Nov 15;16(11):e0258645.
doi: 10.1371/journal.pone.0258645. eCollection 2021.
Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins
Yengkhom Damayanti Devi[SUP] 1 [/SUP], Himanshu Ballav Goswami[SUP] 1 [/SUP], Sushmita Konwar[SUP] 1 [/SUP], Chandrima Doley[SUP] 1 [/SUP], Anutee Dolley[SUP] 1 [/SUP], Arpita Devi[SUP] 1 [/SUP], Chen Chongtham[SUP] 1 2 [/SUP], Dikshita Dowerah[SUP] 3 [/SUP], Vashkar Biswa[SUP] 4 [/SUP], Latonglila Jamir[SUP] 5 [/SUP], Aditya Kumar[SUP] 1 [/SUP], Siddhartha Shankar Satapathy[SUP] 6 7 [/SUP], Suvendra Kumar Ray[SUP] 1 7 [/SUP], Ramesh Chandra Deka[SUP] 3 7 [/SUP], Robin Doley[SUP] 1 [/SUP], Manabendra Mandal[SUP] 1 7 [/SUP], Sandeep Das[SUP] 4 [/SUP], Chongtham Shyamsunder Singh[SUP] 8 [/SUP], Partha Pratim Borah[SUP] 9 [/SUP], Pabitra Nath[SUP] 10 [/SUP], Nima D Namsa[SUP] 1 7 [/SUP]
Affiliations
- PMID: 34780495
- DOI: 10.1371/journal.pone.0258645
Abstract
All approved coronavirus disease 2019 (COVID-19) vaccines in current use are safe, effective, and reduce the risk of severe illness. Although data on the immunological presentation of patients with COVID-19 is limited, increasing experimental evidence supports the significant contribution of B and T cells towards the resolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the availability of several COVID-19 vaccines with high efficacy, more effective vaccines are still needed to protect against the new variants of SARS-CoV-2. Employing a comprehensive immunoinformatic prediction algorithm and leveraging the genetic closeness with SARS-CoV, we have predicted potential immune epitopes in the structural proteins of SARS-CoV-2. The S and N proteins of SARS-CoV-2 and SARS-CoVs are main targets of antibody detection and have motivated us to design four multi-epitope vaccines which were based on our predicted B- and T-cell epitopes of SARS-CoV-2 structural proteins. The cardinal epitopes selected for the vaccine constructs are predicted to possess antigenic, non-allergenic, and cytokine-inducing properties. Additionally, some of the predicted epitopes have been experimentally validated in published papers. Furthermore, we used the C-ImmSim server to predict effective immune responses induced by the epitope-based vaccines. Taken together, the immune epitopes predicted in this study provide a platform for future experimental validations which may facilitate the development of effective vaccine candidates and epitope-based serological diagnostic assays.